File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Oral misoprostol versus placebo for cervical dilatation before vacuum aspiration in first trimester pregnancy

TitleOral misoprostol versus placebo for cervical dilatation before vacuum aspiration in first trimester pregnancy
Authors
KeywordsCervical priming
Oral misoprostol
Issue Date1995
PublisherOxford University Press. The Journal's web site is located at http://humrep.oxfordjournals.org/
Citation
Human Reproduction, 1995, v. 10 n. 5, p. 1220-1222 How to Cite?
AbstractIntravaginal misoprostol has been shown to be effective for cervical priming before a surgically induced abortion. The objective was to investigate the effectiveness of oral misoprostol in cervical dilatation prior to vacuum aspiration between the 6th and 12th weeks of pregnancy. The results showed that in nulliparous patients, the median cervical dilatation in the treatment group (7.8 mm was significantly greater than that in the placebo group (3.7 mm). In multiparous patients, the difference was also statistically significant (9.8 versus 6.0 mm). The ease of dilatation, assessed subjectively by the operating surgeons, was significantly improved in the treatment group. There was also a significant reduction in the duration of the operation and in the mean blood loss in the treatment group. The side-effects encountered in the treatment group were mild and well accepted by the women. Oral misoprostol is an effective and safe method for cervical dilatation prior to vacuum aspiration in first trimester pregnancy. | The effectiveness of oral misoprostol for cervical dilatation prior to first-trimester (6-12 weeks of pregnancy) vacuum aspiration was evaluated in a case-control study of 75 women referred to a Hong Kong clinic for induced abortion. 36 women were randomly assigned to receive misoprostol (400 mcg 12 hours before the procedure), while 39 women were given a placebo; 21 women in the treatment group and 22 controls were nulliparous. Among nulliparous women, median cervical dilatation was significantly greater in the treatment group (7.8 mm) than the placebo group (3.7 mm). In multiparous women, these medians were 9.8 and 6.0 mm, respectively. The ease of further dilatation, subjectively assessed by operating surgeons, was rated easier than normal in 88% of women in the treatment group compared with 26% of controls. There was also a significant reduction in the median duration of vacuum aspiration in nulliparous cases (4.5 minutes) compared with controls (5.5 minutes) and in median blood loss (20 and 28 ml, respectively). Side effects (lower abdominal pain, vaginal spotting, nausea) were mild and well-tolerated in both groups. These findings suggest that oral misoprostol is a safe, cost-effective (US$0.40 per tablet) alternative for cervical priming prior to vacuum aspiration.
Persistent Identifierhttp://hdl.handle.net/10722/87107
ISSN
2015 Impact Factor: 4.621
2015 SCImago Journal Rankings: 2.271
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorNgai, SWen_HK
dc.contributor.authorTang, OSen_HK
dc.contributor.authorLao, Ten_HK
dc.contributor.authorHo, PCen_HK
dc.contributor.authorMa, HKen_HK
dc.date.accessioned2010-09-06T09:25:25Z-
dc.date.available2010-09-06T09:25:25Z-
dc.date.issued1995en_HK
dc.identifier.citationHuman Reproduction, 1995, v. 10 n. 5, p. 1220-1222en_HK
dc.identifier.issn0268-1161en_HK
dc.identifier.urihttp://hdl.handle.net/10722/87107-
dc.description.abstractIntravaginal misoprostol has been shown to be effective for cervical priming before a surgically induced abortion. The objective was to investigate the effectiveness of oral misoprostol in cervical dilatation prior to vacuum aspiration between the 6th and 12th weeks of pregnancy. The results showed that in nulliparous patients, the median cervical dilatation in the treatment group (7.8 mm was significantly greater than that in the placebo group (3.7 mm). In multiparous patients, the difference was also statistically significant (9.8 versus 6.0 mm). The ease of dilatation, assessed subjectively by the operating surgeons, was significantly improved in the treatment group. There was also a significant reduction in the duration of the operation and in the mean blood loss in the treatment group. The side-effects encountered in the treatment group were mild and well accepted by the women. Oral misoprostol is an effective and safe method for cervical dilatation prior to vacuum aspiration in first trimester pregnancy. | The effectiveness of oral misoprostol for cervical dilatation prior to first-trimester (6-12 weeks of pregnancy) vacuum aspiration was evaluated in a case-control study of 75 women referred to a Hong Kong clinic for induced abortion. 36 women were randomly assigned to receive misoprostol (400 mcg 12 hours before the procedure), while 39 women were given a placebo; 21 women in the treatment group and 22 controls were nulliparous. Among nulliparous women, median cervical dilatation was significantly greater in the treatment group (7.8 mm) than the placebo group (3.7 mm). In multiparous women, these medians were 9.8 and 6.0 mm, respectively. The ease of further dilatation, subjectively assessed by operating surgeons, was rated easier than normal in 88% of women in the treatment group compared with 26% of controls. There was also a significant reduction in the median duration of vacuum aspiration in nulliparous cases (4.5 minutes) compared with controls (5.5 minutes) and in median blood loss (20 and 28 ml, respectively). Side effects (lower abdominal pain, vaginal spotting, nausea) were mild and well-tolerated in both groups. These findings suggest that oral misoprostol is a safe, cost-effective (US$0.40 per tablet) alternative for cervical priming prior to vacuum aspiration.en_HK
dc.languageengen_HK
dc.publisherOxford University Press. The Journal's web site is located at http://humrep.oxfordjournals.org/en_HK
dc.relation.ispartofHuman Reproductionen_HK
dc.rightsHuman Reproduction. Copyright © Oxford University Press.en_HK
dc.subjectCervical primingen_HK
dc.subjectOral misoprostolen_HK
dc.titleOral misoprostol versus placebo for cervical dilatation before vacuum aspiration in first trimester pregnancyen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0268-1161&volume=10&issue=5&spage=1220&epage=1222&date=1995&atitle=Oral+misoprostol+versus+placebo+for+cervical+dilatation+before+vacuum+aspiration+in+first+trimester+pregnancyen_HK
dc.identifier.emailHo, PC:pcho@hku.hken_HK
dc.identifier.authorityHo, PC=rp00325en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.pmid7657769-
dc.identifier.scopuseid_2-s2.0-0029052242en_HK
dc.identifier.hkuros3067en_HK
dc.identifier.volume10en_HK
dc.identifier.issue5en_HK
dc.identifier.spage1220en_HK
dc.identifier.epage1222en_HK
dc.identifier.isiWOS:A1995RC65900038-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridNgai, SW=7006074214en_HK
dc.identifier.scopusauthoridTang, OS=7006723402en_HK
dc.identifier.scopusauthoridLao, T=35327208900en_HK
dc.identifier.scopusauthoridHo, PC=7402211440en_HK
dc.identifier.scopusauthoridMa, HK=7403095603en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats